Ketorolac plus Lidocaine vs Lidocaine for pain relief following core needle soft tissue biopsy A CONSORT-compliant double-blind randomized controlled study

被引:0
作者
Chobpenthai, Thanapon [1 ,2 ]
Ingviya, Thammasin [3 ,4 ]
Thanindratarn, Pichaya [2 ]
Jaiwithee, Rattakorn [2 ]
Sutthivaiyakit, Kulwadee [5 ]
机构
[1] Chulabhorn Royal Acad, HRH Princess Chulabhorn Coll Med Sci, Fac Med & Publ Hlth, 906 Kamphaengphet 6 Rd, Bangkok 10210, Thailand
[2] Chulabhorn Hosp, Dept Orthoped, Bangkok, Thailand
[3] Prince Songkla Univ, Fac Med, Dept Family & Prevent Med, Hat Yai, Thailand
[4] Prince Songkla Univ, Fac Med, Med Data Ctr Res & Innovat, Hat Yai, Thailand
[5] Chulabhorn Hosp, Dept Anesthesiol Unit, Bangkok, Thailand
关键词
ketorolac; Lidocaine; local anesthesia; pain intensity; soft tissue biopsy; INTRAVENOUS REGIONAL ANESTHESIA; VISUAL ANALOG SCALE; PHARMACOKINETICS; TROMETHAMINE; MANAGEMENT; INJECTION; HUMANS;
D O I
10.1097/MD.0000000000024721
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Backgrounds: The main objective of this study was to compare the pain control efficacy of local administration of Lidocaine with or without the nonsteroidal anti-inflammatory drug, Ketorolac, and local conventional Lidocaine injection in core needle biopsy of the musculoskeletal tumor. Methods: The current study was a randomized, double-blind controlled clinical trial that included 128 patients with suspected musculoskeletal tumors. Patients were randomly assigned to either the Ketorolac plus Lidocaine (n=64) or Lidocaine group (n=64). The Ketorolac - Lidocaine combination syringe contained 30mg Ketorolac and 2% Lidocaine - adrenaline dosage, and the Lidocaine syringe contained 2% Lidocaine - adrenaline dosage. The level of pain after core needle biopsy was evaluated for each patient at 1, 6, 12, 24, 48, and >48hours by a Visual Analog Scale (VAS). The mean VAS changes over time were compared between the Ketorolac plus Lidocaine and Lidocaine groups using a linear mixed model. Results: baseline information including mean age of patients in Lidocaine group (51.5 +/- 19.4 years) and in Lidocaine - Ketorolac combination group (50.1 +/- 18years), diagnosis (malignant, benign, metastatic, infection), tumor location (upper and lower extremities, back), VAS score 1-hour post-operation (mild and moderate pain) were noted. The VAS score ratings were significantly lower in Lidocaine - Ketorolac combination group when compared to the Lidocaine group during the 1 to 24hours post-operation time period. Conclusion: Patients receiving Lidocaine - Ketorolac combination dosage had significantly lower VAS scores, and these results confirm that local injection of Lidocaine - Ketorolac combination had a superior pain-controlling effect during the first 24hours after the biopsy procedure in comparison to Lidocaine injection alone, as measured by VAS score scale.
引用
收藏
页数:5
相关论文
共 30 条
  • [1] Safety of Local Intracutaneous Lidocaine Anesthesia Used by Dermatologic Surgeons for Skin Cancer Excision and Postcancer Reconstruction: Quantification of Standard Injection Volumes and Adverse Event Rates
    Alam, Murad
    Schaeffer, Matthew R.
    Geisler, Amelia
    Poon, Emily
    Fosko, Scott W.
    Srivastava, Divya
    [J]. DERMATOLOGIC SURGERY, 2016, 42 (12) : 1320 - 1324
  • [2] Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1197/aemj.10.4.390
  • [3] Reliability of the visual analog scale for measurement of acute pain
    Bijur, PE
    Silver, W
    Gallagher, EJ
    [J]. ACADEMIC EMERGENCY MEDICINE, 2001, 8 (12) : 1153 - 1157
  • [4] Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain
    Boonstra, Anne M.
    Preuper, Henrica R. Schiphorst
    Balk, Gerlof A.
    Stewart, Roy E.
    [J]. PAIN, 2014, 155 (12) : 2545 - 2550
  • [5] Ketorolac use for postoperative pain management following lumbar decompression surgery - A prospective, randomized, double-blinded, placebo-controlled trial
    Cassinelli, Ezequiel H.
    Dean, Clayton L.
    Garcia, Ryan M.
    Furey, Christopher G.
    Bohlman, Henry H.
    [J]. SPINE, 2008, 33 (12) : 1313 - 1317
  • [6] Castellsague J, 2012, DRUG SAFETY, V35, P1127, DOI 10.2165/11633470-000000000-00000
  • [7] Catapano Michael S., 1996, Journal of Emergency Medicine, V14, P67, DOI 10.1016/0736-4679(95)02052-7
  • [8] Connelly NR, 1995, YALE J BIOL MED, V68, P95
  • [9] Correll D., 2007, Pain Management, V1, P197, DOI DOI 10.1016/B978-0-7216-0334-6.50022-4
  • [10] David, 1998, Prim Care Update Ob Gyns, V5, P196, DOI 10.1016/S1068-607X(98)00127-9